Oramed Pharmaceuticals Inc Financials
This page shows Oramed Pharmaceuticals Inc (ORMP) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 14 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).
Oramed’s statements read like a cash-funded development program, where reported profit diverges sharply from operating reality.
Across FY2023-FY2025, operating cash flow stayed negative every year while net income flipped between profit and loss, so reported earnings were not describing the cash economics of the business. FY2025 makes the split especially clear: the company reported$64.1M of net income alongside a-$15.1M operating loss, which implies non-operating or non-cash items dominated the bottom line.
Cash burn improved through cost reduction, not revenue scale: operating cash outflow fell to
The balance sheet is financing the wait: current assets of
Financial Health Signals
Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →
Health score ≠ stock price. This rates the quality of Oramed Pharmaceuticals Inc's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.
Oramed Pharmaceuticals Inc has an operating margin of -754.4%, meaning the company retains $-754 of operating profit per $100 of revenue. This below-average margin results in a low score of 22/100, suggesting thin profitability after operating expenses.
Oramed Pharmaceuticals Inc carries a low D/E ratio of 0.16, meaning only $0.16 of long-term debt for every $1 of shareholders' equity. This conservative leverage earns a score of 78/100, indicating a strong balance sheet with room for future borrowing.
With a current ratio of 6.98, Oramed Pharmaceuticals Inc holds $6.98 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 94/100.
While Oramed Pharmaceuticals Inc generated -$9.1M in operating cash flow, capex of $9K consumed most of it, leaving -$9.2M in free cash flow. This results in a low score of 2/100, reflecting heavy capital investment rather than weak cash generation.
Oramed Pharmaceuticals Inc's ROE of 32.1% shows moderate profitability relative to equity, earning a score of 30/100. This is up from -13.0% the prior year.
Oramed Pharmaceuticals Inc scores 2.76, placing it in the grey zone between 1.81 and 2.99. The score is driven primarily by a large market capitalization ($161.9M) relative to total liabilities ($31.1M). This signals moderate financial risk that warrants monitoring.
Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.
Oramed Pharmaceuticals Inc passes 3 of 6 computable financial strength tests (3 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass.
For every $1 of reported earnings, Oramed Pharmaceuticals Inc generates $-0.14 in operating cash flow (-$9.1M OCF vs $64.0M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.
Key Financial Metrics
Earnings & Revenue
Oramed Pharmaceuticals Inc generated $2.0M in revenue in fiscal year 2025.
Oramed Pharmaceuticals Inc's EBITDA was -$15.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 18.9% from the prior year.
Oramed Pharmaceuticals Inc reported $64.0M in net income in fiscal year 2025. This represents an increase of 436.0% from the prior year.
Oramed Pharmaceuticals Inc earned $1.50 per diluted share (EPS) in fiscal year 2025. This represents an increase of 412.5% from the prior year.
Cash & Balance Sheet
Oramed Pharmaceuticals Inc generated -$9.2M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 8.6% from the prior year.
Oramed Pharmaceuticals Inc held $45.9M in cash against $0 in long-term debt as of fiscal year 2025.
Oramed Pharmaceuticals Inc paid $0.25 per share in dividends in fiscal year 2025.
Oramed Pharmaceuticals Inc had 39M shares outstanding in fiscal year 2025. This represents a decrease of 1.6% from the prior year.
Margins & Returns
Oramed Pharmaceuticals Inc's gross margin was 0.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs.
Oramed Pharmaceuticals Inc's operating margin was -754.4% in fiscal year 2025, reflecting core business profitability.
Oramed Pharmaceuticals Inc's net profit margin was 3202.5% in fiscal year 2025, showing the share of revenue converted to profit.
Oramed Pharmaceuticals Inc's ROE was 32.1% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is up 45.1 percentage points from the prior year.
Capital Allocation
Oramed Pharmaceuticals Inc invested $6.4M in research and development in fiscal year 2025. This represents an increase of 0.9% from the prior year.
Oramed Pharmaceuticals Inc spent $4.7M on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents an increase of 90.9% from the prior year.
Oramed Pharmaceuticals Inc invested $9K in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 50.0% from the prior year.
ORMP Income Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Revenue | N/A | N/A | N/A | N/A | $2.0M | N/A | N/A | N/A |
| Cost of Revenue | N/A | N/A | N/A | N/A | $2.0M | N/A | N/A | N/A |
| Gross Profit | N/A | N/A | N/A | N/A | $13K | N/A | N/A | N/A |
| R&D Expenses | $1.6M | N/A | $1.2M+11.5% | $1.0M-53.1% | $2.2M | N/A | $2.2M+55.5% | $1.4M |
| SG&A Expenses | $2.1M | N/A | $1.3M-12.4% | $1.5M-36.9% | $2.3M | N/A | $847K-50.0% | $1.7M |
| Operating Income | -$3.7M | N/A | -$2.4M+2.5% | -$2.5M+44.7% | -$4.5M | N/A | -$3.1M+1.5% | -$3.1M |
| Interest Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | $261K |
| Income Tax | $11.1M | N/A | $11.1M+8879.4% | -$126K-121.6% | $584K | N/A | $1.1M-30.7% | $1.6M |
| Net Income | $38.3M | N/A | $48.4M+264.2% | $13.3M+273.9% | -$7.6M | N/A | -$19.6M-313.0% | $9.2M |
| EPS (Diluted) | $0.91 | N/A | $1.13+264.5% | $0.31+263.2% | $-0.19 | N/A | $-0.48-318.2% | $0.22 |
ORMP Balance Sheet
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | $268.8M+16.5% | $230.9M+4.7% | $220.5M+36.4% | $161.7M+9.6% | $147.5M-5.0% | $155.3M-5.9% | $165.1M-10.4% | $184.2M |
| Current Assets | $68.2M-48.9% | $133.3M-2.1% | $136.1M+37.5% | $99.0M-24.7% | $131.5M-8.2% | $143.2M+0.3% | $142.8M-6.8% | $153.3M |
| Cash & Equivalents | $13.2M-71.3% | $45.9M-11.9% | $52.2M+230.3% | $15.8M-78.8% | $74.5M+36.9% | $54.4M+29.3% | $42.1M-50.3% | $84.8M |
| Inventory | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Goodwill | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $30.6M-1.8% | $31.1M+80.8% | $17.2M+140.5% | $7.2M+6.4% | $6.7M-25.4% | $9.0M+4.3% | $8.6M+20.7% | $7.2M |
| Current Liabilities | $10.6M-44.7% | $19.1M+211.9% | $6.1M+65.7% | $3.7M-32.8% | $5.5M-3.4% | $5.7M+7.8% | $5.3M+41.3% | $3.7M |
| Long-Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $238.3M+19.3% | $199.7M-1.7% | $203.3M+31.5% | $154.5M+9.7% | $140.8M-3.7% | $146.3M-6.5% | $156.4M-11.6% | $177.1M |
| Retained Earnings | -$85.1M+31.0% | -$123.4M-0.7% | -$122.6M+28.3% | -$171.0M+7.2% | -$184.3M-4.3% | -$176.6M-6.1% | -$166.4M-13.4% | -$146.8M |
ORMP Cash Flow Statement
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$2.9M-525.5% | -$466K+71.3% | -$1.6M+54.0% | -$3.5M-0.5% | -$3.5M-84.1% | -$1.9M+73.1% | -$7.1M-442.1% | $2.1M |
| Capital Expenditures | $5K+150.0% | $2K | $0-100.0% | $4K+33.3% | $3K-72.7% | $11K+120.0% | $5K | $0 |
| Free Cash Flow | -$2.9M-523.9% | -$468K+71.2% | -$1.6M+54.1% | -$3.5M-0.5% | -$3.5M-83.2% | -$1.9M+73.0% | -$7.1M-442.3% | $2.1M |
| Investing Cash Flow | -$19.5M-1057.2% | -$1.7M-104.4% | $38.4M+169.9% | -$54.9M-332.3% | $23.6M+53.1% | $15.4M+145.0% | -$34.3M-136.2% | $94.7M |
| Financing Cash Flow | -$10.4M-158.5% | -$4.0M-1010.5% | -$361K | N/A | N/A | -$1.2M+7.4% | -$1.3M+95.8% | -$30.6M |
| Dividends Paid | $10.4M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Share Buybacks | N/A | $4.0M+1010.5% | $361K | N/A | N/A | $1.2M | N/A | N/A |
ORMP Financial Ratios
| Metric | Q1'26 | Q4'25 | Q3'25 | Q2'25 | Q1'25 | Q4'24 | Q3'24 | Q2'24 |
|---|---|---|---|---|---|---|---|---|
| Gross Margin | N/A | N/A | N/A | N/A | 0.7% | N/A | N/A | N/A |
| Operating Margin | N/A | N/A | N/A | N/A | -225.0% | N/A | N/A | N/A |
| Net Margin | N/A | N/A | N/A | N/A | -382.1% | N/A | N/A | N/A |
| Return on Equity | 16.1% | N/A | 23.8%+15.2pp | 8.6%+14.0pp | -5.4% | N/A | -12.5%-17.7pp | 5.2% |
| Return on Assets | 14.2% | N/A | 21.9%+13.7pp | 8.2%+13.4pp | -5.2% | N/A | -11.9%-16.9pp | 5.0% |
| Current Ratio | 6.45-0.5 | 6.98-15.3 | 22.25-4.6 | 26.81+2.9 | 23.94-1.3 | 25.19-1.9 | 27.08-14.0 | 41.06 |
| Debt-to-Equity | 0.13-0.0 | 0.16+0.1 | 0.08+0.0 | 0.050.0 | 0.05-0.0 | 0.060.0 | 0.06+0.0 | 0.04 |
| FCF Margin | N/A | N/A | N/A | N/A | -176.1% | N/A | N/A | N/A |
Similar Companies
Frequently Asked Questions
What is Oramed Pharmaceuticals Inc's annual revenue?
Oramed Pharmaceuticals Inc (ORMP) reported $2.0M in total revenue for fiscal year 2025. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.
Is Oramed Pharmaceuticals Inc profitable?
Yes, Oramed Pharmaceuticals Inc (ORMP) reported a net income of $64.0M in fiscal year 2025, with a net profit margin of 3202.5%.
What is Oramed Pharmaceuticals Inc's EBITDA?
Oramed Pharmaceuticals Inc (ORMP) had EBITDA of -$15.0M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.
What is Oramed Pharmaceuticals Inc's gross margin?
Oramed Pharmaceuticals Inc (ORMP) had a gross margin of 0.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.
What is Oramed Pharmaceuticals Inc's operating margin?
Oramed Pharmaceuticals Inc (ORMP) had an operating margin of -754.4% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.
What is Oramed Pharmaceuticals Inc's net profit margin?
Oramed Pharmaceuticals Inc (ORMP) had a net profit margin of 3202.5% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.
Does Oramed Pharmaceuticals Inc pay dividends?
Yes, Oramed Pharmaceuticals Inc (ORMP) paid $0.25 per share in dividends during fiscal year 2025.
What is Oramed Pharmaceuticals Inc's return on equity (ROE)?
Oramed Pharmaceuticals Inc (ORMP) has a return on equity of 32.1% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.
What is Oramed Pharmaceuticals Inc's free cash flow?
Oramed Pharmaceuticals Inc (ORMP) generated -$9.2M in free cash flow during fiscal year 2025. This represents a -8.6% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.
What is Oramed Pharmaceuticals Inc's operating cash flow?
Oramed Pharmaceuticals Inc (ORMP) generated -$9.1M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.
What are Oramed Pharmaceuticals Inc's total assets?
Oramed Pharmaceuticals Inc (ORMP) had $230.9M in total assets as of fiscal year 2025, including both current and long-term assets.
What are Oramed Pharmaceuticals Inc's capital expenditures?
Oramed Pharmaceuticals Inc (ORMP) invested $9K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.
How much does Oramed Pharmaceuticals Inc spend on research and development?
Oramed Pharmaceuticals Inc (ORMP) invested $6.4M in research and development during fiscal year 2025.
What is Oramed Pharmaceuticals Inc's current ratio?
Oramed Pharmaceuticals Inc (ORMP) had a current ratio of 6.98 as of fiscal year 2025, which is generally considered healthy.
What is Oramed Pharmaceuticals Inc's debt-to-equity ratio?
Oramed Pharmaceuticals Inc (ORMP) had a debt-to-equity ratio of 0.16 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.
What is Oramed Pharmaceuticals Inc's return on assets (ROA)?
Oramed Pharmaceuticals Inc (ORMP) had a return on assets of 27.7% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.
What is Oramed Pharmaceuticals Inc's cash runway?
Based on fiscal year 2025 data, Oramed Pharmaceuticals Inc (ORMP) had $45.9M in cash against an annual operating cash burn of $9.1M. This gives an estimated cash runway of approximately 60 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.
What is Oramed Pharmaceuticals Inc's Altman Z-Score?
Oramed Pharmaceuticals Inc (ORMP) has an Altman Z-Score of 2.76, placing it in the Grey Zone (moderate risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.
What is Oramed Pharmaceuticals Inc's Piotroski F-Score?
Oramed Pharmaceuticals Inc (ORMP) has a Piotroski F-Score of 3 out of 6 computable signals; 3 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.
Are Oramed Pharmaceuticals Inc's earnings high quality?
Oramed Pharmaceuticals Inc (ORMP) has an earnings quality ratio of -0.14x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.
How financially healthy is Oramed Pharmaceuticals Inc?
Oramed Pharmaceuticals Inc (ORMP) scores 39 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.